JY
ACTU

Jeff Yass’s Actuate Therapeutics ACTU Stock Holding History

Jeff Yass’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.1K Buy
+28,182
New +$65.3K ﹤0.01% 12880
2026
Q1 		– Sell
-10,253
Closed -$62.7K – 14350
2025
Q4 		$62.7K Buy
+10,253
New +$70.4K ﹤0.01% 11674
2025
Q2 		– Sell
-47,634
Closed -$322K – 13929
2025
Q1 		$322K Buy
+47,634
New +$382K ﹤0.01% 9908

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Jeff Yass's ACTU Position: Q2 2026 in Review

Jeff Yass opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 28,182 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #12880 among its holdings. This is a return to the name: Jeff Yass previously reported a position in ACTU as recently as Q4 2025.

Jeff Yass first reported a position in ACTU in Q1 2025 and has held it in 3 quarters since. The position peaked at $322K in Q1 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Jeff Yass held 28,182 shares of Actuate Therapeutics worth $43.1K as of Q2 2026.
  • Actuate Therapeutics was a new Jeff Yass position in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12880 holding.
  • Jeff Yass first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Jeff Yass's Actuate Therapeutics position peaked at $322K in Q1 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.